Cargando…

Soluble PD-L1 Expression After Intravenous Treatment of Cancer Patients With Selenite in Phase I Clinical Trial

A high expression level of programmed death-ligand 1 (PD-L1) is observed in different types of cancers (particularly lung cancer). Soluble (s)PD-L1 may be used as a prognostic marker and a target for anti-cancer immunity, as well as, predicting gene therapy or systemic immunotherapy in blocking the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razaghi, Ali, Mansouri, Ladan, Brodin, Ola, Björnstedt, Mikael, Lundahl, Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203154/ https://www.ncbi.nlm.nih.gov/pubmed/35720000 http://dx.doi.org/10.3389/fonc.2022.906134

Ejemplares similares

Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites
por: Breuer, Olof, et al.
Publicado: (2023)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
por: Razaghi, Ali, et al.
Publicado: (2023)

Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study
por: Brodin, Ola, et al.
Publicado: (2015)

Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite
por: Brodin, Ola, et al.
Publicado: (2020)

“Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19”
por: Mansouri, Ladan, et al.
Publicado: (2022)

Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
por: Nilsonne, Gustav, et al.
Publicado: (2009)

The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines
por: Lendvai, Gábor, et al.
Publicado: (2020)

Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells
por: Misra, Sougat, et al.
Publicado: (2016)

Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy
por: Razaghi, Ali, et al.
Publicado: (2021)

Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha
por: Razaghi, Ali, et al.
Publicado: (2021)

Leukocyte Proliferation and Immune Modulator Production in Patients with Chronic Kidney Disease
por: Mansouri, Ladan, et al.
Publicado: (2013)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Adhesion molecule cross‐linking and cytokine exposure modulate IgE‐ and non‐IgE‐dependent basophil activation
por: Kalm, Frida, et al.
Publicado: (2020)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

Proteomic Analysis of Pleural Effusions from COVID-19 Deceased Patients: Enhanced Inflammatory Markers
por: Razaghi, Ali, et al.
Publicado: (2022)

Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease – a randomized trial
por: Mansouri, Ladan, et al.
Publicado: (2017)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

B cell and monocyte phenotyping: A quick asset to investigate the immune status in patients with IgA nephropathy
por: Sendic, Senka, et al.
Publicado: (2021)

Impact of monocyte‐related modulators and kidney function on mortality in hospitalized patients with COVID‐19
por: Sendic, Senka, et al.
Publicado: (2022)

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
por: Claaß, Luise Victoria, et al.
Publicado: (2022)

Early Phase I Study of a (99m)Tc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer
por: Xing, Yan, et al.
Publicado: (2019)

Interaction of alkylmercuric compounds with sodium selenite. I. Metabolism of ethylmercuric chloride administered alone and in combination with sodium selenite in rats.
por: Brzeźnicka, E A, et al.
Publicado: (1981)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Activation of Basophils Is a New and Sensitive Marker of Biocompatibility in Hemodialysis
por: Aljadi, Zenib, et al.
Publicado: (2014)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Li, Zhitao, et al.
Publicado: (2021)

Effects of redox modulation by inhibition of thioredoxin reductase on radiosensitivity and gene expression
por: Selenius, Markus, et al.
Publicado: (2012)

Cytosinium hydrogen selenite
por: Takouachet, Radhwane, et al.
Publicado: (2014)

Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients
por: Kgokolo, Mahlatse C. M., et al.
Publicado: (2022)

Selenite Induces Cell Cycle Arrest and Apoptosis via Reactive Oxygen Species-Dependent Inhibition of the AKT/mTOR Pathway in Thyroid Cancer
por: Cheng, Zhen, et al.
Publicado: (2021)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020)

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
por: Tabana, Yasser, et al.
Publicado: (2021)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
por: Zhang, Hanqun, et al.
Publicado: (2022)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n3bqesgqcupra7eraq88vj8frm